Novo Nordisk Shares Surge on New Obesity Drug Results
Market Reaction to Clinical Breakthrough Novo Nordisk shares climbed significantly in European trading today following the release of promising clinical trial data for an experimental weight-loss injectable. The Danish pharmaceutical company reported that participants in the study experienced an average body weight reduction of 22%, signaling a major advancement in obesity treatment protocols. Context of…